New study discovers how to prevent chemotherapy-associated neuropathic pain in colon cancer

A high percentage of cancer patients develop hypersensitivity to cold and touch in the extremities and mouth as a result of chemotherapy.

30-Aug-2022 - Researchers at the Instituto de Neurociencias (IN), a joint center of the Consejo Superior de Investigaciones Científicas (CSIC) and the Universidad Miguel Hernández (UMH), have discovered how to prevent neuropathic pain associated with chemotherapy in the treatment of colon cancer, the second ...

Researchers explore epigenetic influences of chronic pain

23-Jun-2016 - Despite the enormous societal impact of chronic pain, present treatment options are limited to nonsteroidal anti-inflammatory drugs (NSAIDS), opioids, anticonvulsants and antidepressants, which provide pain relief to only about half of patients. Furthering the problem, prescription opioid ...

A new role for sodium in the brain

Findings identify a novel pharmacological target for drug development

26-Aug-2013 - Researchers at McGill University have found that sodium – the main chemical component in table salt – is a unique “on/off” switch for a major neurotransmitter receptor in the brain. This receptor, known as the kainate receptor, is fundamental for normal brain function and is implicated in ...

Affectis Granted Patent for AFC-5128, other P2X7 Antagonists

27-Jan-2012 - Affectis Pharmaceuticals AG announced that the European Patent Office has granted a key patent for its oral brain-penetrant P2X7 antagonist AFC-5128 which is being developed for the treatment of neuropathic pain and multiple sclerosis.The European patent EP2105164 is related to the composition of ...

ExonHit Extends Strategic Collaboration with Allergan

Agreement to extend the collaboration until December 2013

08-Nov-2011 - ExonHit S.A. y announced the extension of its existing drug discovery collaboration with Allergan Sales, LLC. The collaboration was initiated in December 2002, and extended several times. It now is further extended until December 2013. The collaboration will continue to focus on the ...

Marijuana component could ease pain from chemotherapy drugs

10-Oct-2011 - A chemical component of the marijuana plant could prevent the onset of pain associated with drugs used in chemo therapy, particularly in breast cancer patients, according to researchers at Temple University's School of Pharmacy.The researchers published their findings, "Cannabidiol Prevents the ...

Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Postherpetic Neuralgia

20-Sep-2011 - Spinifex Pharmaceuticals, an Australian pain drug development company, announced the first patients have been treated in its Phase 2 clinical trial of EMA401 in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing ...

Evotec receives Milestone as Boehringer Ingelheim starts Phase I clinical trial in Pain

03-Jun-2011 - Evotec AG announced that a back-up compound in its strategic alliance with Boehringer Ingelheim has advanced into a Phase I clinical trial. Evotec will receive a milestone payment of EUR 2.0 million. The compound, which was discovered and optimised within the alliance, is being developed as a ...

Sun Pharma Announces USFDA Tentative Approval for Generic Cymbalta

30-Nov-2010 - Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules. These generic duloxetine hydrochloride ...

Galapagos and University of Bristol enter drug discovery collaboration in chronic pain

20-Jul-2010 - Galapagos NV and the University of Bristol announced a new drug discovery collaboration aimed at developing treatments for chronic pain associated with diabetes (diabetic neuropathic pain). Galapagos' service division BioFocus will provide hit-to-lead and lead optimization services for a ...